johnson & johnson (nyse: jnj) announced positive topline results from the phase 2b anthem-uc study evaluating icotrokinra (jnj-2113), an investigational targeted oral peptide that blocks the il-23 receptor, in adults with moderately to severely active ulcerative colitis. the study met its primary endpoint, demonstrating clinical response in all dose groups, with the highest dose achieving a response rate of 63.5% at week 12 compared to 27% for placebo. clinical remission was achieved in 30.2% of patients in the highest dose group versus 11.1% for placebo.

icotrokinra was well tolerated, with adverse events occurring at similar rates between treatment and placebo groups. results continued to improve through week 28.

comprehensive results are being prepared for presentation at upcoming medical conferences.

source: johnson & johnson